Impact Therapeutics Announces Completion of Series D1 Financing |
| March 14, 2022 | March 2022 Bond Updates |
|
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors... |
| View more at: https://www.prnewswire.com:443/news-releases/impact-therapeutics-announces-completion-of-series-d1-financing-301501583.html |
| Related News |
|